Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01761565 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab
A Phase 1 study of Plasma Concentrations, sponsored by Talphera.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT01761565 is a Phase 1 study of Plasma Concentrations that has completed, run by Talphera. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01761565, a Phase 1 study of Plasma Concentrations, has completed, sponsored by Talphera.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Determine the plasma concentration profile after single and multiple dosing of Sufentanil NanoTabs
Conditions Studied
Interventions
- DRUG Single dose of SUF NT 15 mcg
- DRUG 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes
Study Locations (1)
Kansas
- PRA - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01761565
The ClinicalTrials.gov registry entry for NCT01761565 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Talphera, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plasma Concentrations appearing as the primary indexed condition, and to 2 interventions - of which Single dose of SUF NT 15 mcg is the first listed.
NCT01761565 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT01761565 about?
NCT01761565 is a clinical study titled "Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab". Determine the plasma concentration profile after single and multiple dosing of Sufentanil NanoTabs
What is the current status of trial NCT01761565?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2013-01. Estimated completion is 2013-02.
What conditions does trial NCT01761565 study?
This clinical trial studies the following conditions: Plasma Concentrations.
What interventions are being tested in trial NCT01761565?
The interventions under investigation include: Single dose of SUF NT 15 mcg (DRUG), 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes (DRUG).
Who is sponsoring clinical trial NCT01761565?
This trial is sponsored by Talphera, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01761565 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.